The 2nd baby had grunting, and respiratory distress soon after birth. She was admitted in NICU and started with iv fluid, iv antibiotics and O2 through nasal prong. Investigations revealed covid 19 RT-PCR negative but covid 19 IgG-7.89, IL6-184.0 pg/ml, D Dimer – 919, LDH-593, Trop-I- 155.1 ng/L, NTproBNP-567.1, procalcitonin- 0.866 ng/ml with B/L haziness on CXRay. The mother also had covid IgG -7.89. The baby was treated with IVlg, SC LMWH, and supportives. The baby responded to treatment well and discharged.

Results Both the babies responded well to IVlg, iv antibiotics and supportives. We have use iv dexona in 1st case.

On follow up all the laboratory parameters of the 1st baby was normal and she was gaining weight. The 2nd baby was on LMWH as her d Dimer, APTT and covid IgG were high. Clinically she is asymptomatic, feeding well and gaining weight.

Conclusions Though cytokine storm is dangerous consequence of covid 19 in Preterm newborns timely diagnosis and appropriate treatment can reduce the morbidity and mortality of the disease.

**372 USAGE OF HIGH FLOW NASAL CANNULA IN PAEDIATRIC PATIENTS OUTSIDE ICU SETTING**

Siew Sing Chua, Lay Chin Tan, Fong Chiao Lai, Nor Duyana Ismail, Noraini Ab Rahman, Hasdalina Ishak. Malaysia

Background High-flow nasal cannula (HFNC) is a non-invasive positive pressure ventilation which delivers adjustable mixture of heated and humidified air and oxygen at rates that exceed spontaneous inspiratory flow. It’s easy to initiate, relatively safe, and usually well tolerated by children (1). A lot of studies have suggested that HFNC may reduce the work of breathing (1). Early initiation of HFNC has been associated with reduced rate of endotracheal intubation.

Objectives This study aims to provide an overview of HFNC usage in paediatrics general ward setting, outside ICU setting.

Methods A retrospective study was carried out to evaluate the usage of HFNC in paediatric patients in HSIP general ward settings from April 2019 to March 2020.

Results A total of 177 children’s record (boys: 112, girls: 65, age: 1 month to 12 years old) were analysed. A total of 112 patients were referral from district hospital, while 55 patients were referral from our emergency department.

From the analysis, we noted the age group of 12 to 24 months had the highest number of admissions requiring HFNC. Most of the patients were put on HFNC immediately upon admission to ward. The duration of its usage ranges from 2–4 days (interquartile range (IQR)), with median of 3 days. Length of hospital stay were 6 days (IQR: 4 to 8 days). Multiple linear regression analysis showed that duration of HFNC usage and delaying its initiation >6 hours were associated with significantly longer hospital stay (p-value <0.001).

Among the indications for the usage of HFNC, pneumonia is the main cause, followed by acute bronchiolitis, heart failure, sepsis and laryngomalacia. Almost one third (38%) of the patients that required HFNC had underlying disease(s), mainly respiratory disease. SpO2 on arrival were mostly 96% (IQR: 92 to 99%). Respiratory rates were analysed according to age group as well.

The median white cell count (WCC) is 12.96 × 10³/uL (IQR: 9.67 to 17.27), while C-reactive protein (CRP) is 22 mg/L (IQR: 10.91 to 52.62). Linear regression was used to analyse the correlation between these two parameters, which showed that WCC and CRP are two independent variables.

Conclusions HFNC is an excellent choice of NIV in providing respiratory support in district hospital with no or very limited intensive care unit. Our study showed that it is relatively safe to use with regular vital signs monitoring, with occasionally some patients requiring continuous SpO2 monitoring. Detailed studies on its indication, safety protocol and cost effectiveness are needed to improve the outcome of patients.

**375 HEPATOPATHY-THROMBOCYTOPENIA SYNDROME (HTS) AFTER ACTINOMYCIN-D THERAPY IN WILMS TUMOUR: A RARE COMPLICATION WITH FAVOURABLE OUTCOME**

Fong Chiao Lai, Siew Sing Chua, Sarwany Mohamad, Arrifin Nasir, Noraini AB Rahman. Malaysia

Background Hepatopathy-thrombocytopenia syndrome (HTS) is characterized by fever, hepatopathy (hepatomegaly with abnormal liver function tests), ascites, weight gain, jaundice, and thrombocytopenia (platelet count less than 25 × 10³/μL). The incidence is about 1.4% in a child with Wilms tumour receiving actinomycin D. Its mortality is 5–20%.

The mechanism is not well understood. Histopathological markers of HTS are obliteration of small hepatic venules and damage to endothelial cells.

One of the prominent features of HTS is severe thrombocytopenia. It could be the first sign of detecting ‘at risk child’ of developing full-blown syndrome. Thrombocytopenia related to actinomycin D has been well documented.

Risk factors are younger age, administration of actinomycin D, radiotherapy, GSTM1-null genotype and MDR1 gene mutations.

Objectives To report a case of HTS post actinomycin D in a patient with underlying Wilms tumour.

Methods This is a case of a 4-year-old girl, newly diagnosed left Wilms tumour COG stage II, underwent left nephrectomy and started on weekly chemotherapy. Three days after she received her 3rd cycle of vincristine and actinomycin D, she crashed to emergency department in encephalopathic state with symptomatic hypoglycemia. Physical examination revealed hepatosplenomegaly and gross ascites but there was no jaundice. Her blood investigations showed low platelet count of 7 × 10³/μL, severe transaminases AST 5381U/L, ALT 2035U/L, and coagulopathy but normal renal profile. Her serum ammonia was 125μmol/L with compensated metabolic acidosis. CT